KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Net Cash Flow: 2009-2025

Historic Net Cash Flow for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Sep 2025 value amounting to -$30.1 million.

  • Vertex Pharmaceuticals' Net Cash Flow fell 104.75% to -$30.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$336.6 million, marking a year-over-year increase of 94.30%. This contributed to the annual value of -$5.8 billion for FY2024, which is 3355.88% down from last year.
  • Vertex Pharmaceuticals' Net Cash Flow amounted to -$30.1 million in Q3 2025, which was down 112.57% from $239.4 million recorded in Q2 2025.
  • Vertex Pharmaceuticals' Net Cash Flow's 5-year high stood at $1.3 billion during Q4 2022, with a 5-year trough of -$4.6 billion in Q2 2024.
  • Moreover, its 3-year median value for Net Cash Flow was -$30.1 million (2025), whereas its average is -$512.0 million.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Net Cash Flow surged by 558.10% in 2022, and later plummeted by 639.74% in 2024.
  • Vertex Pharmaceuticals' Net Cash Flow (Quarterly) stood at $524.8 million in 2021, then soared by 146.61% to $1.3 billion in 2022, then crashed by 159.63% to -$771.7 million in 2023, then rose by 18.54% to -$628.6 million in 2024, then tumbled by 104.75% to -$30.1 million in 2025.
  • Its last three reported values are -$30.1 million in Q3 2025, $239.4 million for Q2 2025, and $82.7 million during Q1 2025.